Tag: pharmaceuticals
-
Mylan Acquires Generic Injectables Manufacturer for $1.6B
Mylan Inc., a producer of generic and specialty branded drugs in Pittsburgh, will acquire Agila Specialties in Bangalore, India, a developer of generic inectable drugs and division of Strides Arcolab Ltd. Mylan will pay $1.6 billion cash for Agila Specialties, with up to $250 million in contingent payments possible later on. Mylan offers some 1,100…
-
Roche Increasing Access to Clinical Trial Results
The pharmaceutical company Roche, based in Switzerland, will increase access to its clinical trial data for third-party researchers. The company also promises access to clinical data for its flu medication Tamiflu, after review by independent scientists, for which the British medical journal BMJ and evidence-based medicine organization Cochrane Collaboration have long-standing requests for access. In…
-
Pharmas Recall Anemia Drug for Dialysis Patients
Affymax Inc. in Palo Alto, California and Takeda Pharmaceuticals Company in Osaka, Japan are recalling its drug Omontys in the U.S. after reported cases of anaphylaxis, a serious and life-threatening allergic reaction. The recall is being coordinated with the U.S. Food and Drug Administration. Omontys, the branded form of the drug peginesatide, is a synthetic…
-
Merck, Samsung to Collaborate on Biosimilars
The pharmaceutical company Merck & Co. in New Jersey and Samsung Bioepis Co. in Seoul, South Korea agreed on a deal for licensing and taking to market non-branded biologic therapies called biosimilars. While the companies released an outline of the financial arrangements, the dollar amount of the agreement was not disclosed. Biosimilars are treatments and…
-
Biotechs to Partner on Cancer Therapy, Drug Production
The biotechnology companies iBio Inc. in Newark, Delaware and Caliber Biotherapeutics in Bryan, Texas agreed to combine their plant-based genomic drug discovery and development technologies to produce new therapeutics, beginning with a cancer drug. Financial aspects of the deal were not disclosed. iBio’s platform, called iBio Launch, uses plant biology to harness gene expression for…
-
Lozenges, Tobacco-Free Snuff Help Tobacco Chewers Quit
Researchers at the Mayo Clinic in Rochester, Minnesota found nicotine lozenges and tobacco-free snuff could get smokeless tobacco users to quit their habits, even when some users started out with no intention of quitting. The team led by Mayo Clinic’s Jon Ebbert published its findings in this month’s issue of the journal Addictive Behaviors (paid…
-
Roche, Biotech to Partner on Growth Hormone Disorders
The Swiss pharmaceutical company Roche will license a compound developed by biotechnology company Chiasma Inc., based in New York and Jerusalem, to treat the hormonal disease acromegaly and neuroendocrine tumors. The deal has a total potential value to Chiasma of $595 million. Chiasma develops drugs for oral administration previously available in injection form. The company’s…
-
Challenge Seeks Discontinued Drugs to Treat Rare Diseases
A new challenge on InnoCentive asks for ideas on repurposing drugs no longer in development as therapies for rare diseases other than cancer. The sponsor of the competition, an unnamed biopharmaceutical company, will award a total purse of $10,000 to the best proposals. The deadline for submissions is 11 March 2013 (free registration required). Rare…
-
Personalized Chemotherapy Devised from Patients’ Tumors
Researchers at Johns Hopkins University in Baltimore developed a new lab technique to personalize the selection of chemotherapy drugs, with cell lines based on patients’ own tumors and genetically engineered mice. The findings of the team led by Johns Hopkins professor James Eshleman appear online in a recent issue of the journal Clinical Cancer Research…
-
Report: Common Action Needed Against Fake, Substandard Drugs
A report from the Institute of Medicine, part of the National Academies in the U.S., calls for a new agreement on an international code of practice on drug quality to counter the growing health risks from illegimiate medicines. Among the recommendations in the report are a mandatory drug tracking system and tightening the licensing requirements…